Whole Genome Amplification MarketThe global whole genome amplification (WGA) market is on track for substantial growth, with ...

The provision will enable whole genome sequencing for neonatal and paediatric patients in intensive care units within 48 ...

GeneDx is targeting a big market for its genetic testing: every newborn baby. The 24-old-company is developing a plan to make the testing common at birth.

Transforming Genomic Medicine with Unprecedented Speed, Accuracy, and Accessibility - PanOmiQ Sets a New Standard with ...

Upper tract urothelial carcinoma (UTUC) is an aggressive disease that is challenging to biopsy and diagnose, frequently yielding nondiagnostic cytology and tissue specimens. Therefore, UTUC is often ...

GAITHERSBURG, Md. - GeneDx (NASDAQ:WGS), a genomic insights company with a market capitalization of $1.95 billion, announced the introduction of its ultraRapid Whole Genome Sequencing service, which ...

A stand-alone sequencing approach was accurate, cost effective and efficient for analyzing resistant pathogens and ...

From understanding hereditary diseases to predicting drug responses, sequencing helps researchers uncover the subtle language ...

GeneDx specializes in whole genome sequencing. That involves looking at about 20,000 genes that make up a genome, the instructions to build and sustain a human. More common multi-gene panels ...